Direct comparison of GeneXpert MTB/RIF (Cepheid) with probeTEC (Becton-Dickinson) and Taqman MTB (Roche) for detection of TB bacteria

Hoffmann, Harald; Hofmann-Thiel, Sabine; Turaev, Laziz; Esenalieva, A; Abdullaeva, M; Mirazim, K; Antonenka, Uladzimir

doi:10.1055/s-0032-1302666

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, many advances in analytical techniques were made and the Cepheid GeneXpert MTB test now allows detection of M.tuberculosis directly from sputum sample within 3-4 hours. It was approved by FDA and is claimed to be more sensitive than smear analysis [24,25]. An already established PCR detection of M.tuberculosis, though rather expensive, is very sensitive, requires about two hours to complete, and is being used in remote locations in resource-limited settings [24].…”

Section: Introductionmentioning

confidence: 99%

Centrifugal Microfluidic Platform for Rapid, Multiplexed Detection of TB and HIV Biomarkers in Whole Blood Samples

Litvinov¹,

St²,

Gj³

et al. 2017

J Bioengineer & Biomedical Sci

View full text Add to dashboard Cite

Infection with Mycobacterium Tuberculosis represents a significant threat to people with immune disorders, such as HIV-positive individuals, and can result in significant health complications or death if not diagnosed and treated early. We present a centrifugal microfluidic platform for multiplexed detection of tuberculosis and HIV biomarkers in human whole blood with minimal sample preparation and a sample-to-answer time of 30 minutes. This multiplexed assay was developed for the detection of two M.tuberculosis secreted proteins, whose secretion represents an active and ongoing infection, as well as detection of HIV p24 protein and human anti-p24 antibodies. The limit of detection for this multiplex assay is in the pg/mL range for both HIV and M.tuberculosis proteins, making this assay potentially useful in the clinical diagnosis of both HIV and Tuberculosis proteins indicative of active infection. Antigen detection for the HIV assay sensitivity was 89%, the specificity 85%. Serological detection had 100% sensitivity and specificity for the limited sample pool. The centrifugal microfluidic platform presented here offers the potential for a portable, fast and inexpensive multiplexed diagnostic device that can be used in resource-limited settings for diagnosis of TB and HIV.

show abstract

Section: Introductionmentioning

confidence: 99%